Research & Development is Being Called Upon by WHO

Research & Development is Being Called Upon by WHO

The World Health Organization (WHO) has been very busy lately with a list of some of the most threatening bacterial infections out there. They want to guide and promote more research and development on these infections in hopes of finding antibiotics that can help fight against them. This is just a small portion of what is being used to address the growing global resistance to these types of antimicrobial drugs.

WHO’s Assistant Director-General stated, “This list is a new tool to ensure R&D responds to urgent public health needs. “Antibiotic resistance is growing, and we are fast running out of treatment options. If we leave it to market forces alone, the new antibiotics we most urgently need are not going to be developed in time.”

Divided into 3 categories: medium, high and critical, the lists aim to promote more funding, research and development in antibiotics aimed at treating these bacteria strains. Many of the bacteria on the list are gram-negative types that resist multiple types of antibiotics.

Some of the more severe bacteria on the list pose the most threats within nursing homes, hospitals and other care areas. These patients may be on ventilators, have weakened immune systems or have blood catheters. Many of these types of infections oftentimes become severe or even deadly to the patients that contract them. These bacteria are listed in the critical section, along with others due to the fact that they can resist many types of antibiotics for treatment.

Other countries, not just the US have taken action in this fight against bacterial infections. The Federal Minister of Health in Germany, Hermann Gröhe stated, “We have to take joint action today for a healthier tomorrow. Therefore, we will discuss and bring the attention of the G20 to the fight against antimicrobial resistance. WHO’s first global priority pathogen list is an important new tool to secure and guide research and development related to new antibiotics.”

In short, by focusing efforts in research and development on these specific strains of bacteria, these infections will happen much less and those suffering from them can have the specific antibiotics needed to overcome them. Without these publicly-funded research groups, these bacteria will continue to harm the general public in many countries throughout the world. This is why research and development are both important for this process now.

Part of the Bacterial Infection List Provided by WHO:

CRITICAL

 Pseudomonas aeruginosa, Enterobacteriaceae, Acinetobacter baumannii

 HIGH

 Salmonellae, Enterococcus faecium, Neisseria gonorrhoeae, Staphylococcus aureus

 MEDIUM

Haemophilus influenzae, Streptococcus pneumoniae

Samantha Skinner is a freelance writer and internet marketer providing quality content and keeping up with the latest in world news. With interests in medical, family, travel and technology, she is passionate about what she writes about. You can follow her on Facebook.

French Drug Market Declining As Government Favors Generics 

French Drug Market Declining As Government Favors Generics 

What Is Patient Centricity and What Is It's Role in Clinical Trials?

What Is Patient Centricity and What Is It's Role in Clinical Trials?